Asif Ali - 30 Sep 2026 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Reporting relationship: Chief Financial Officer
Issuer ticker: PTGX
Reported as of: 30 Sep 2026
Net transaction value: -$8,312,294
SEC form: 4
Accepted by SEC: 02 Oct 2026, 16:10:06 UTC
Prior SEC filing: 21 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Gosling, Attorney-in-Fact for Asif Ali

Filing notes and source

Key filing fact

Asif Ali filed Form 4 for Protagonist Therapeutics, Inc (PTGX) on 02 Oct 2026.

Key facts

This page summarizes Asif Ali's Form 4 filing for Protagonist Therapeutics, Inc (PTGX).
10 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 02 Oct 2026, 16:10.

Change

Previous filing in this sequence was filed on 21 Apr 2026.
Current net transaction value: -$8,312,294.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001921163 Primary reporting owner

Ali Asif

Relationship: Chief Financial Officer
Address: C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK
Signature: /s/ Matthew Gosling, Attorney-in-Fact for Asif Ali
Signature date: 02 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PTGX transaction

Common Stock

Options Exercise

Transaction value
Shares: +9,229
Change %: +16%
Price: $38.98^*
Shares after: 68,232
Date: 30 Sep 2026
Ownership: Direct
Footnotes: F1

PTGX transaction

Common Stock

Options Exercise

Transaction value
Shares: +28,438
Change %: +42%
Price: $23.42^*
Shares after: 96,670
Date: 30 Sep 2026
Ownership: Direct
Footnotes: F1

PTGX transaction

Common Stock

Options Exercise

Transaction value
Shares: +15,650
Change %: +16%
Price: $19.19^*
Shares after: 112,320
Date: 30 Sep 2026
Ownership: Direct
Footnotes: F1

PTGX transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,312
Change %: +4.7%
Price: $12.17^*
Shares after: 117,632
Date: 30 Sep 2026
Ownership: Direct
Footnotes: F1

PTGX transaction

Common Stock

Sale

Transaction value: -$1,785,593
Shares: -12,595
Change %: -11%
Price: $141.77
Shares after: 105,037
Date: 30 Sep 2026
Ownership: Direct
Footnotes: F1, F2

PTGX transaction

Common Stock

Sale

Transaction value: -$6,526,701
Shares: -46,034
Change %: -44%
Price: $141.78
Shares after: 59,003
Date: 30 Sep 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTGX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -9,229
Change %: -24%
Price: $0.000000^*
Shares after: 29,291
Date: 30 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,229
Exercise price: $38.98
Footnotes: F4

PTGX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -28,438
Change %: -36%
Price: $0.000000^*
Shares after: 49,562
Date: 30 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,438
Exercise price: $23.42
Footnotes: F5

PTGX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -15,650
Change %: -23%
Price: $0.000000^*
Shares after: 51,150
Date: 30 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,650
Exercise price: $19.19
Footnotes: F6

PTGX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -5,312
Change %: -17%
Price: $0.000000^*
Shares after: 25,235
Date: 30 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,312
Exercise price: $12.17
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 7 footnotes

Footnote F1

The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

Footnote F2

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.21 to $143.31. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F3

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.16 to $143.45. Upon request by the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F4

The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

Footnote F5

The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

Footnote F6

The stock option is fully vested.

Footnote F7

The stock option vests in 48 equal monthly installments following January 16, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.